?Oclacitinib Maleate (CAS 1640292-55-2)?
?? ?ChemicalBook Product Profile?

?? ?Product Overview?

?Oclacitinib Maleate? (C??H??N?O?S) is a ?selective JAK1 inhibitor? with a molecular weight of ?453.51 g/mol?. This ?white crystalline powder? (≥99% purity, HPLC-validated) is specifically formulated for ?veterinary use?, effectively treating allergic dermatitis and pruritus in dogs by targeting JAK1-dependent cytokines. It minimizes off-target effects on JAK2/JAK3, ensuring safety and efficacy. Available in ?1kg/5kg/25kg? sealed packaging, stable for ?2 years? under dry, light-protected storage (-20°C recommended).

?Google Keywords?: Oclacitinib Maleate CAS 1640292-55-2, JAK1 Inhibitor API Supplier, Veterinary Dermatology Drug Intermediate, GMP-Certified Animal Health Raw Material

? ?Key Advantages?

       ?? ?High Selectivity?

• IC50 of ?10 nM for JAK1? | 74-fold selectivity over JAK2/JAK3.
  ?? ?Pharmaceutical-Grade Purity?

• ≥99% purity (HPLC/NMR validated) | Complies with ?EP/USP? standards.
  ?? ?Stability Assurance?

• Maintains potency for ?2 years? under recommended storage conditions.

?? ?Application Fields?

1. ?Veterinary Medicine?: Core API for oral tablets targeting canine allergic dermatitis and pruritus.

2. ?Pharmaceutical R&D?: Key intermediate in JAK inhibitor development and preclinical studies.

3. ?Global API Supply?: Bulk production for veterinary drug manufacturers.

?? ?Quality Certifications?

• ?Testing Methods?: HPLC, NMR, mass spectrometry, microbial limit testing.

• ?Certifications?: ?GMP?, ?ISO 9001?, and ?ICH stability guidelines? compliance.

?? ?Market Trends?

The ?global veterinary dermatology market? is projected to grow at ?7.5% CAGR (2025-2030)?, driven by rising pet ownership and demand for targeted therapies. JAK inhibitors like Oclacitinib dominate ?30% of the veterinary anti-inflammatory drug segment?, with Asia-Pacific as the leading API production hub.

?? ?Contact us for COA, bulk pricing, and custom synthesis!